loader2
Partner With Us NRI

Gujarat Themis Biosyn Ltd share Price Today

Company details

495.00
520.00
149.60
520.00
6M Return 170.31%
1Y Return 216.85%
Mkt Cap.(Cr) 3,673.97
Volume 111,905
Div Yield 0.30%
OI
-
OI Chg %
-
Volume 111,905

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Gujarat Themis Biosyn announced Q4FY23 & FY23 results:

  • Q4FY23:
    • Revenue from Operations stood at Rs 28.17 crore in Q4FY23, as against Rs 28.76 crore in Q4FY22
    • EBITDA for the quarter was Rs 14.93 crore as against Rs 13.08 crore in Q4FY22, increase of 14.12%.
    • EBITDA Margin stood at 52.98%, up by 751 bps
    • Q4FY23 PAT stood at Rs 11.69 crore as against profit of Rs 9.79 crore in Q4FY22
    • EPS for the quarter stood at Rs 8.05
  • FY23:
    • Revenue from Operations stood at Rs 148.97 crore in FY23, vs Rs 114.85 crore in FY22, up 29.71%
    • EBITDA for FY23 was Rs 74.22 crore as against Rs 58.05 crore in FY22, increase of 27.86%
    • EBITDA Margin stood at 49.82%
    • FY23 PAT stood at Rs 57.97 crore as against PAT of Rs 43.62 crore in FY22
    • EPS for the year stood at Rs 39.90

 

 

Result PDF

View Other Company Results

Gujarat Themis Biosyn Ltd shares SWOT Analysis

Strengths (9)

  • Strong Momentum: Price above short, medium and long term moving averages
  • New 52 week high today
  • Good quarterly growth in the recent results

Weakness (4)

  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years

Opportunity (1)

  • Highest Recovery from 52 Week Low

Threats (1)

  • High PE (PE > 40)

Resistance and support

R1 518.8
R2 531.9
R3 543.8
Pivot

506.92

S1 493.8
S2 481.9
S3 468.8
EMA SMA
435.3
408.7
374.8
318.6
417.0
407.8
381.6
297.4
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
MC JAIN INFOSERVICES PRIVATE LIMITED Bulk Purchase 2023-12-27 215 490000 BSE
PHARMACEUTICAL BUSINESS GROUP I LTD Bulk Sell 2023-12-27 215.35 3000000 BSE
MANJU PAREKH Bulk Purchase 2017-04-21 50.19 75000 BSE
Name Category Shares
Pharmaceutical Business Group (India) Ltd PROMOTER 47.02%
Themis Medicare Limited PROMOTER 23.19%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Gujarat Themis Biosyn Ltd Stocks COMPARISON

Financials( in Cr) Gujarat Themis Biosyn Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 505.75 1,471.00 1,544.85 4,504.05 1,088.65
% Change 1.01 -2.19 -0.96 0.54 1.41
Mcap Cr 3,673.97 352,942.18 124,726.09 119,568.56 109,543.66
Revenue TTM Cr 148.97 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 57.97 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 61.51 36.06 29.57 74.29 28.02
1 Year Return 216.85 46.84 52.77 25.64 96.45
ROCE 60.86 16.79 14.76 19.30 16.25
ROE 45.92 16.46 10.66 14.89 14.05
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 149.14 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 33,341.08 2,221.69
LAST 3M 102,344.89 -28,029.53
LAST 6M 175,303.31 -12,219.28
LAST 12M 288,302.63 96,022.29

Gujarat Themis Biosyn Ltd Information

Stock PE (TTM)
61.51
Promoter Holding
70.86%
Book Value
27.7209
ROCE
60.86%
ROE
45.92%
Description
  • Promoted by Kantilal Shah, Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is being actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990. However, problems relating to purity levels, yield and imports put the company in the red and it became a BIFR case in 1990. Subsequently, it was taken over by a group consisting of Lyka Labs, Themis Chemicals, Kopran and Cadila. Also, Yuhan Corporation, South Korea, brought in technology and finance for running GTBL. During 1995-96 the paid-up share capital increased from Rs 11.25 crores to Rs 11.60 crores after allotment of 350,000 Equity shares of Rs 10 each at a premium of Rs 20 per share to the financial institutions by way of conversion of fund interst term loan. During the year installed capacity of rifamysin-S was increased to 90 mtpa and expansion of rifampicin was achieved to the maximum capacity of 120 mtpa. It also commenced operations of its new pharmaceutical division and launched a wide range of anti-tuberculosis products and other antibiotics. The company is constantly identifying new areas for diversification and also capacity expansion of exisiting product in order to further reduction in cost of production and increase in turnover.

Registered Address

69/C GIDC Industrial Estate, Valsad Dist, VAPI, Gujarat, 396195

Tel : 91-260-2430027
Email : gtblmumbai:gtbl.in; admin:gtbl.co.in
Website : http://www.gtbl.in
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 506879
NSE Code : GUJTHEMIS
Book Closure Date (Month) : Sep
BSE Group : T
ISIN : INE942C01045

FAQ’s on Gujarat Themis Biosyn Ltd Shares

You can buy Gujarat Themis Biosyn Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Gujarat Themis Biosyn Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 20, 2024 04:01 PM the closing price of Gujarat Themis Biosyn Ltd was Rs.505.75.

The latest PE ratio of Gujarat Themis Biosyn Ltd as of Jun 20, 2024 04:01 PM is 61.51

The latest PB ratio of Gujarat Themis Biosyn Ltd as of Jun 20, 2024 04:01 PM is 0.06

The 52-week high of Gujarat Themis Biosyn Ltd share price is Rs. 520.00 while the 52-week low is Rs. 149.60

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 20, 2024 04:01 PM, the market cap of Gujarat Themis Biosyn Ltd stood at Rs. 3,673.97.

Download App

Download Our App

Play Store App Store
market app